Key Highlights:
- Abbott has partnered with Novo Nordisk to commercialize Extensior in India, a brand of semaglutide developed and manufactured by Novo Nordisk. The collaboration combines Novo Nordisk’s GLP-1 expertise with Abbott’s strong distribution network to expand access to advanced diabetes therapies.
- Extensior is a second brand of Ozempic, one of the world’s most widely prescribed GLP-1 receptor agonists. The therapy is approved as an adjunct to diet and exercise for adults with type-2 diabetes, offering significant HbA1c reduction, weight-loss benefits, and reduced cardiovascular and kidney risks.
- The partnership aims to address India’s rapidly growing diabetes burden, affecting more than 100 million people, by improving access to evidence-based metabolic treatments and strengthening diabetes management across the country
Implications:
Extensior catapults Abbott into the GLP-1 frenzy, grabbing prime shelf space before generics from Eris/Natco crash prices by half—think explosive Tier-2 growth via Abbott’s unmatched endocrinologist network.
Novo locks in loyalty with dual-brand strategy despite CDSCO promo crackdowns, outmaneuvering Eli Lilly while everyday Indians finally access blockbuster metabolic fixes.
This sparks a diabetes revolution, funneling PE cash into digital adherence tools and obesity platforms as India eyes Saudi exports in the $2B+ metabolic gold rush.
Source: Abbott
